Sign In
Buy SLN
$7.27
-0.260 (-3.45%)
At Close: Jun 23, 2026
Silence Therapeutics Stock Rises On Positive Blood Cancer Drug Data
10:47am, Friday, 12'th Jun 2026
Silence Therapeutics Plc (NASDAQ:SLN) shares are up during Friday's session. On Thursday, the company highlighted follow-up data from its Phase 1 SANRECO study of divesiran.
Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today presented
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today
Silence Therapeutics to Participate in Jefferies Global Healthcare Conference
08:00am, Wednesday, 27'th May 2026
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today
Silence Therapeutics to Participate in H.C. Wainwright BioConnect Investor Conference
08:00am, Tuesday, 12'th May 2026
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
08:00am, Thursday, 07'th May 2026
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
09:52am, Thursday, 16'th Apr 2026
Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Given Average Recommendation of “Moderate Buy” by Brokerages
04:43am, Friday, 03'rd Apr 2026
Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ: SLN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the sto
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
04:26am, Wednesday, 11'th Mar 2026
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
10:56am, Thursday, 05'th Mar 2026
The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results
07:30am, Thursday, 05'th Mar 2026
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financ
Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Hold” from Brokerages
02:02am, Sunday, 18'th Jan 2026
Silence Therapeutics PLC Sponsored ADR (NASDAQ: SLN - Get Free Report) has earned a consensus recommendation of "Hold" from the six brokerages that are presently covering the stock, Marketbeat reports
Silence Therapeutics Announces Leadership Changes
08:13am, Monday, 15'th Dec 2025
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering
Silence Therapeutics: Divesiran Targets High-Burden PV
06:03am, Tuesday, 18'th Nov 2025
Silence Therapeutics is advancing its lead RNAi drug, divesiran, for polycythemia vera, with a fully enrolled Phase 2 trial and results expected in Q3 2026. SLN boasts a strong cash position ($100M+),
Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
07:30am, Thursday, 06'th Nov 2025
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering
